Media stories about M.D.C. (NYSE:MDC) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. M.D.C. earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave press coverage about the construction company an impact score of 46.4477321183559 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Focus on conservation efforts to avoid man-animal conflict: Suresh Prabhu (moneycontrol.com)
- A Look At State House & Senate Races In Miami-Dade (miami.cbslocal.com)
- Child Airlifted In Miami-Dade (patch.com)
- Constable: Suburban birder honked off by plans to change conservation law (dailyherald.com)
- 1 hospitalized following collision in SW Miami-Dade (wsvn.com)
Several brokerages recently issued reports on MDC. ValuEngine raised shares of M.D.C. from a “strong sell” rating to a “sell” rating in a report on Thursday. Zacks Investment Research raised shares of M.D.C. from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a report on Tuesday, August 7th. Wedbush reduced their target price on shares of M.D.C. from $34.00 to $33.00 and set a “neutral” rating on the stock in a report on Thursday, August 2nd. UBS Group reissued a “buy” rating and set a $35.00 target price (up from $32.00) on shares of M.D.C. in a report on Friday, May 4th. Finally, JPMorgan Chase & Co. raised shares of M.D.C. from an “underweight” rating to a “neutral” rating and set a $36.00 target price on the stock in a report on Friday, July 13th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $35.38.
MDC traded down $0.19 during trading on Friday, reaching $31.14. 366,576 shares of the company’s stock were exchanged, compared to its average volume of 435,241. M.D.C. has a one year low of $26.45 and a one year high of $37.45. The company has a debt-to-equity ratio of 0.72, a current ratio of 9.59 and a quick ratio of 2.49. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 12.07, a PEG ratio of 0.45 and a beta of 1.47.
M.D.C. (NYSE:MDC) last posted its earnings results on Wednesday, August 1st. The construction company reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.27. M.D.C. had a net margin of 6.91% and a return on equity of 13.82%. The firm had revenue of $749.60 million for the quarter, compared to analyst estimates of $713.27 million. During the same period in the previous year, the firm posted $0.64 EPS. The company’s revenue for the quarter was up 15.5% compared to the same quarter last year. equities research analysts predict that M.D.C. will post 3.79 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 22nd. Shareholders of record on Wednesday, August 8th will be issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date is Tuesday, August 7th. M.D.C.’s payout ratio is 46.51%.
M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.
Recommended Story: Google Finance Portfolio
Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.